Breaking Down 3 New Senate Bills Targeting Drug Prices
Law360 (April 18, 2019, 7:36 PM EDT) -- Three bills were introduced in the Senate last week that sponsors say aim to lower drug prices by speeding up approval of generic drugs, including by limiting stays of generic drug approvals tied to Hatch-Waxman Act patent cases. Here’s a look at how the bills would work.
Sen. Bill Cassidy, R-La., a gastroenterologist, introduced all three bills April 11 with numerous bipartisan co-sponsors and said in a statement that "to lower the cost of drugs, we need to increase competition. Getting generics to market faster increases access and saves money for patients and taxpayers."
The branded drug industry group Pharmaceutical Research...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!